Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID‐19
| Autor: | Avni Uygar Seyhan, Fatih Doğanay, Nurdan Papila Topal, Erdal Resit Yilmaz, Rohat Ak |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Coronavirus disease 2019 (COVID-19) Prolonged QT Azithromycin QT interval Antimalarials Electrocardiography Young Adult Pharmacotherapy Internal medicine Humans Medicine cardiovascular diseases Pandemics Aged Retrospective Studies Aged 80 and over Dose-Response Relationship Drug SARS-CoV-2 business.industry COVID-19 Retrospective cohort study Hydroxychloroquine General Medicine Middle Aged Prognosis Anti-Bacterial Agents COVID-19 Drug Treatment Long QT Syndrome Cardiology Drug Therapy Combination Female business Follow-Up Studies medicine.drug Cohort study |
| Zdroj: | Journal of the College of Physicians and Surgeons Pakistan. 30:153-157 |
| ISSN: | 1681-7168 1022-386X |
| DOI: | 10.29271/jcpsp.2020.supp2.s153 |
| Popis: | Objective To assess and identify the risk of prolonged QT about hydroxychloroquine (HQ) and azithromycin (AZ) used in the treatment of patients with COVID-19. Study design Cohort study. Place and duration of study Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkey, from March to May 2020. Methodology One hundred and forty-four patients with the diagnosis of COVID-19, confirmed by Rt-PCR (reverse transcription-polymerase chain reaction), were restrospectively reviewed. Patients who were hospitalised, received HQ or HQ plus AZ treatment, had a baseline electrocardiogram (ECG), and had at least one ECG after treatment were included in the study. Patients with missing data were excluded. Results Fifty-one (35.4%) patients were given hydroxychloroquine monoterapy (HQ), 93 (64.6%) were given hydroxychloroquine plus azithromycin (HA), and 70 (48.6%) were women. Pre-treatment mean QTc measurements were calculated as 410.61 ± 29.44 milliseconds (ms) for HQ group and 412.02 ± 25.37 ms for HA group, while the mean values of post-treatment QTc measurements were calculated as 432.31 ± 33.97 ms for HQ group and 432.03 ± 27.0 ms for the HA group. Post-treatment QTc measurements of both HA group and HQ group were prolonged compared to pre-treatment measurements. Ventricular arrhythmia was not observed in any patient. Conclusion For COVID-19, no globally accepted definite treatment has yet been found. Both of hydroxychloroquine monotherapy and hydroxychloroquine plus azithromycin treatment regimens cause QTc measurement to increase at a statistically significant level. We concluded that this increase in QTc did not cause ventricular arrhythmia. Key Words: COVID-19, QTc interval, Hydroxychloroquine, Azithromycin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|